within Pharmacolibrary.Drugs.ATC.L;

model L04AC23
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.6,
    Cl             = 0.003,
    adminDuration  = 600,
    adminMass      = 0.064,
    adminCount     = 1,
    Vd             = 0.0045,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0004166666666666667,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Olokizumab is a humanized monoclonal antibody targeting interleukin-6 (IL-6), used for the treatment of adults with moderate to severe active rheumatoid arthritis who have had an inadequate response or intolerance to disease-modifying antirheumatic drugs (DMARDs). It was approved in Russia in 2020 for rheumatoid arthritis and is under clinical development elsewhere.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic estimates for olokizumab in adult patients with rheumatoid arthritis based on typical monoclonal antibody PK behavior and limited published clinical data.</p><h4>References</h4><ol><li>Kosmas Kretsos, Georg Golor, Astrid Jullion, Matthew Hickling, Suzanne McCabe, Stevan Shaw, Joby Jose, Ruth Oliver,Safety and pharmacokinetics of olokizumab, an anti-IL-6 monoclonal antibody, administered to healthy male volunteers: A randomized phase I study.,Clinical pharmacology in drug development,2014<a href='https://pubmed.ncbi.nlm.nih.gov/27129012/'>https://pubmed.ncbi.nlm.nih.gov/27129012/</a></li><li>Svetlana Agachi, Marina Beloukhova, Diane Mould, Maria Lemak, Sergey Grishin, Mikhail Samsonov,Inflammation-mediated drug interactions of olokizumab and cytochrome P450 activities in patients with rheumatoid arthritis.,British journal of clinical pharmacology,2024<a href='https://pubmed.ncbi.nlm.nih.gov/38984761/'>https://pubmed.ncbi.nlm.nih.gov/38984761/</a></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L04AC23;
